Next Generation Biotherapeutics Market to Grow with a CAGR of 12.07% through 2028

Increasing incidence of cancer and increasing R&D activities using NGS technologies is expected to drive the Global Next Generation Biotherapeutics Market growth in the forecast period, 2024-2028.

 

According to TechSci Research report, “Next Generation Biotherapeutics Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Next Generation Biotherapeutics Market stood at USD 4.31 billion in 2022 and is anticipated to grow with a CAGR of 12.07% in the forecast period, 2024-2028. The global market for Next Generation Biotherapeutics is experiencing substantial growth, attributed to technological advancements in this field and the increasing prevalence of chronic diseases. Furthermore, the growth of the Next Generation Biotherapeutics market is driven by the rise in healthcare expenditure and the expansion of research and development activities.

                                                                                             

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Next Generation Biotherapeutics Market.”

 

The market growth is primarily driven by the increasing prevalence of chronic diseases like rheumatoid arthritis, inflammatory bowel disorder, Crohn’s disease, and cancer. According to a research report by Medscape in January 2022, the annual incidence rate of rheumatoid arthritis is approximately 3 cases per 10,000 people, with a global prevalence rate of around 1%. Additionally, the American Cancer Society reported in January 2021 that more than 1.9 million new cancer cases are expected to be diagnosed and 609,360 cancer-related deaths are projected in the United States in 2022. Next Generation Biotherapeutics, known for their enhanced efficacy, improved safety, and targeted treatment delivery, are widely used in the treatment of chronic diseases and rare disorders, particularly cancer and autoimmune disorders. Consequently, the market for next-generation antibodies is expected to expand significantly due to the growing prevalence of chronic diseases and rare disorders, with next-generation antibodies being the predominant therapy.

Prominent biotechnology and pharmaceutical companies are increasingly investing in the development of therapeutic antibodies to combat inflammatory diseases, cancer, and autoimmune disorders. For example, in November 2022, Seagen announced the FDA approval of brentuximab vedotin (ADCETRIS) for children with previously untreated high-risk Hodgkin lymphoma. In the same month, ImmunoGen received accelerated approval from the FDA for ELAHERE (mirvetuximab soravtansine-gynx) for the treatment of platinum-resistant ovarian cancer in adults. Moreover, F-star Therapeutics announced a license agreement with Takeda in July 2022, granting Takeda exclusive rights to research, develop, and commercialize a bispecific next-generation antibody targeting an immuno-oncology target. In March 2022, Bayer revealed its plans to invest EUR 2 billion over the next three years to expand its next-generation manufacturing capabilities.The global demand for Next Generation Biotherapeutics is expected to grow significantly during the forecast period, driven by their success in treating chronic conditions such as cancer and autoimmune diseases. Scientific advancements have played a crucial role in improving the effectiveness of antibody therapeutics. Additionally, technological developments in this field and the increasing prevalence of chronic diseases have contributed to substantial market growth. Furthermore, the market expansion is fueled by rising healthcare expenditure and growing research and development activities.

The rising prevalence of chronic disorders is another significant factor driving the market for Next Generation Biotherapeutics. The integration of technology to support research and development activities is expected to further propel industry growth in the coming years. Many governments are increasing funding and grants for research in the antibody therapeutics market. Coupled with the growing healthcare spending in developed and developing countries, this will drive demand growth during the forecast period.

 

The Global Next Generation Biotherapeutics Market is segmented into therapeutic area and technology, regional distribution, and company.Based on technology, the Antibody-Drug Conjugates (ADC) segment is projected to hold the largest market share in the Next Generation Biotherapeutics market. ADCs represent a significant advancement in this field as they combine the cytotoxic potential of chemotherapy with the favorable properties of antibodies, resulting in highly specific and efficient therapeutic options. ADC technology is predominantly used in the manufacturing of Next Generation Biotherapeutics for cancer treatment. These therapies involve linking an anti-cancer drug or therapeutic substance to an antibody or antibody fragment.

Notably, sacituzumab govitecan, an antibody-drug conjugate composed of a humanized anti-Trop-2 antibody conjugated to SN38, has shown promising results as an effective and well-tolerated agent for metastatic triple-negative breast cancer patients. This demonstrates the potential of ADCs as a novel therapy. The growing demand for antibody-based cancer treatments, coupled with the rising global incidence of breast cancer, advancements in technology, and an increasing number of ADCs undergoing clinical trials, is expected to drive the dominance of the antibody-drug conjugates (ADC) segment in the market. Breast cancer currently ranks as the most common cancer worldwide, accounting for 12.5% of all new annual cancer cases. In the United States alone, an estimated 287,850 new cases of invasive breast cancer and 51,400 new cases of non-invasive (in situ) breast cancer are expected to be diagnosed among women.

The rising demand for antibody therapeutics has led to a surge in new drug approvals for ADCs. Various players in the industry are actively engaged in the development of Next Generation Biotherapeutics using ADC technology, employing different strategies. For example, Mersana Therapeutics Inc. recently announced a partnership with Janssen Pharmaceutical Companies to advance novel ADCs for the treatment of various cancers. Similarly, ImmunoGen Inc. has entered into a multi-year research collaboration with Oxford BioTherapeutics to develop innovative antibody-drug conjugates. These collaborations are driving the growth of the segment and boosting the revenue of the Next Generation Biotherapeutics market in the forecast period.

 

Based on region, North America segment is expected to grow during the forecast period. North America is projected to maintain its dominance in the overall Next Generation Biotherapeutics market during the forecast period. This can be attributed to various factors, including the increasing prevalence of autoimmune diseases, higher healthcare spending, introduction of new products, and continuous growth in research and development activities for the application of these therapeutics in treating different disorders.

 

The rising incidence of chronic conditions like cancer and asthma is also driving the Next Generation Biotherapeutics market. According to a report published in September 2022 by the Asthma and Allergy Foundation of America, approximately 25 million people in the United States suffer from asthma each year, accounting for one in every thirteen Americans. Moreover, as reported by Breast Cancer.Org in October 2022, as of January 2022, there are over 3.8 million women in the U.S. with a history of breast cancer. Hence, the increasing prevalence of chronic diseases in the region is contributing to the growth of this sector.

Furthermore, the presence of prominent companies in the region, expedited approval processes for Next Generation Biotherapeutics, and access to reputable research centers all contribute to the expansion of the market. According to an article published in November 2022 in Silicon Republic, the U.S. FDA has approved its 100th monoclonal antibody therapeutic as of 2021. For instance, in August 2022, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) received approval in the United States for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or experienced disease recurrence during or within six months of completing adjuvant chemotherapy. Additionally, in December 2022, Pyxis Oncology, Inc. obtained clearance from the U.S. FDA to initiate Phase 1 clinical trials for its Investigational New Drug (IND) application of PYX-201, a novel antibody-drug conjugate (ADC) product candidate. The market is expected to advance in the coming years, driven by multiple approvals and a pipeline of several products. Moreover, the presence of advanced healthcare infrastructure and well-established direct reimbursement policies is also anticipated to contribute significantly to the market's revenue throughout the forecast period.

 

Major companies operating in Global Next Generation Biotherapeutics Market are:

• Xencor, Inc.
• Regenxbio & Neurimmune AG
• Takeda Pharmaceutical Company Limited
• Pfizer, Inc.
• AstraZeneca Plc.
• F. Hoffmann-La Roche AG
• Kyowa Kirin Co., Ltd
• Seattle Genetics, Inc
• ImmunoGen, Inc
• Ono Pharmaceuticals Co, Ltd

 

Download Free Sample Report

Customers can also request for 10% free customization on this report.

 

“The future of the global Next Generation Biotherapeutics Market looks promising, with significant advancements expected in the fields of gene therapy, cell therapy, and immunotherapy. Technology plays a critical role in this growth, with innovations in genetic sequencing and bioinformatics predicting the creation of more targeted, effective treatments. Additionally, the increasing prevalence of chronic diseases around the world and a growing understanding of the human genome contribute to the demand for these therapies. However, the market also faces challenges, including complex regulatory landscapes and the high cost of therapies. Despite these hurdles, the market is expected to witness substantial growth in the coming years, transforming the landscape of healthcare and treatment.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Next Generation Biotherapeutics Market Segmented By Therapeutic Area (Oncology, Autoimmune/ Inflammatory Diseases), By Technology (Antibody-Drug Conjugates, Bispecific Antibodies, Antibody Fragments, Antibody-like Proteins, Others), By Region and Competition, Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Next Generation Biotherapeutics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Next Generation Biotherapeutics Market.

Contact

Mr. Ken Mathews         

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656                                                     

Email: [email protected]               

Website: www.techsciresearch.com